Veterinary Biomedical Research (VBR) Building 305
12:10pm on May 15, 2018
"Sea Change: Navigating the Waters of Cancer Drug Development from Bench to Bedside in the Age of Immunotherapy"
Samuel C. Blackman, MD, PhD
Senior Vice President, Head of Clinical Development
Silverback Therapeutics, Inc.
Sam Blackman is a physician-scientist trained in pediatric hematology-oncology and pediatric neuro-oncology. For nearly 10 years he has been focused on the early clinical development of novel cancer therapeutics and has held various positions of increasing responsibility within the pharmaceutical and biotechnology industry. In his present role at Silverback Therapeutics he is responsible for end-to-end clinical development of new protein-based immunotherapeutics for cancer. Prior to this role he was Senior Medical Director at Juno Therapeutics where he was responsible for clinical development of novel cellular immunotherapeutics for leukemia, including chimeric antigen receptor (CAR) T cell therapies and high-affinity T cell receptor (TCR) therapies. He was responsible for the pediatric development strategy for dabrafenib and trametinib while at GlaxoSmithKline, which represent one of the earliest industry-sponsored “basket trials” for pediatric cancer. Dr. Blackman is a graduate of the pediatric hematology/oncology fellowship program at the Dana-Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Cincinnati Children’s Hospital Medical Center. He received his MD and PhD degrees at the University of Illinois at Chicago College of Medicine and Department of Pharmacology, and his undergraduate degree in philosophy from the University of Chicago.